A5071048526- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Carcinogens and Genotoxicity Assessment
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- DNA Repair Mechanisms
- Blood Coagulation and Thrombosis Mechanisms
- Virus-based gene therapy research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- DNA and Nucleic Acid Chemistry
- CAR-T cell therapy research
- Hemostasis and retained surgical items
- Skin Protection and Aging
- Renal and related cancers
- Hematopoietic Stem Cell Transplantation
- Metal complexes synthesis and properties
- Acute Myeloid Leukemia Research
- Cancer-related gene regulation
- Glioma Diagnosis and Treatment
- Sesquiterpenes and Asteraceae Studies
- Genetics, Aging, and Longevity in Model Organisms
- Neonatal Health and Biochemistry
- Renal cell carcinoma treatment
- Viral Infectious Diseases and Gene Expression in Insects
University of California, Davis
2015-2025
University of California Davis Medical Center
2005-2024
The University of Texas Southwestern Medical Center
1982-2021
Southwestern Medical Center
1982-2021
University of Cincinnati Medical Center
2021
Atrium Health Wake Forest Baptist
2021
American Society of Hematology
2021
Thrombosis Research Institute
2019
UC Davis Health System
2016-2017
University of Mississippi Medical Center
2017
The prevention of bleeding with adequately sustained levels clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in treatment hemophilia.
Normal (IMR-90) and simian virus 40-transformed (VA-13) human embryo cells were treated with antitumor nitrosoureas, the effects on cell viability DNA compared. All six nitrosoureas tested more toxic to VA-13 than IMR-90 as measured by decrease in proliferation or colony formation. The capable of generating alkylisocyanates produced a smaller difference between types did derivatives lacking this capacity. damage was alkaline elution four chloroethylnitrosoureas. Whereas exhibited...
Abstract— The induction of DNA single‐strand breaks in normal human fibroblasts exposed to monochromatic wavelengths from 240–546 nm was measured by the alkaline elution assay. cells were irradiated at 1°C prevent both repair induced and formation enzymatically through excision repair. cultures also washed with while suspended phosphate buffered saline damaging photoproducts medium components. action spectrum for strand breakage found exhibit one peak 265 nm, consistent absorption, a second...
Background The association between diagnostic X-ray exposures early in life and increased risk of childhood leukaemia remains unclear. Methods This case–control study included children aged 0–14 years diagnosed with acute lymphoid (ALL, n = 711) or myeloid (AML, 116) from 1995 to 2008. Controls were randomly selected the California birth registry individually matched cases respect date birth, sex, Hispanic ethnicity maternal race. Conditional logistic regression analyses performed assess...
Tobacco smoke contains carcinogens known to damage somatic and germ cells. We investigated the effect of tobacco on risk childhood acute lymphoblastic leukemia (ALL) myeloid (AML), especially subtypes prenatal origin such as ALL with translocation t(12;21) or high-hyperdiploidy (51-67 chromosomes).
In June 1984, the Pediatric Oncology Group (POG) initiated a pilot study (8498) using high-dose cytarabine (HdA; 3 g/m2) for intensification of early therapy in childhood acute myelogenous leukemia (AML) (group I). Remission induction consisted two courses daunorubicin, (Ara-C), and thioguanine (DAT). Postremission four sequential courses, each consisting (1) doses HdA (HdA4) followed by asparaginase (L-Asp), (2) etoposide (VP) plus azacytidine (Az), (3) prednisone, vincristine,...
Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression high-activity factor IX variant (FIX-R338L, or FIX-Padua) in phase 1-2a study. The long-term safety and efficacy this are not known. In 12-month study, 15 participants severe moderately B (factor coagulant activity, ≤2% normal value) received elaparvovec at dose 5×1011 genomes (vg) per kilogram body weight; thereafter, could...
Summary Perioperative clotting factor replacement is administered to reverse the inherent haemostatic defect in persons with haemophilia (PWH), potentially increasing their risk for developing venous thromboembolism (VTE) postoperatively. It was our objective determine prevalence of VTE PWH undergoing total hip or knee arthroplasty (THA, TKA). Patients A B who underwent THA TKA were enrolled this prospective, multicentre observational cohort study. Lower extremity duplex ultrasound performed...
Abstract Introduction FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly previously untreated patients (PUPs). No inhibitors developed clinical trials treated with simoctocog alfa (Nuwiq), a fourth-generation recombinant produced human cell line. Methods The NuProtect study investigated immunogenicity of PUPs. was prospective, multinational, open-label, non-controlled, phase III study. PUPs severe A (FVIII:C <1%) any age and...
Haemophilia A or B patients with inhibitors have been treated FVIIa-containing bypassing agents for over 20 years. However, due to uncertainty regarding dose response and thrombotic risk, the use of a gradual, titrated, minimal dosing strategy remains prevalent, potentially hampering early haemostasis.Evaluate dose-dependent efficacy, safety immunogenicity activated eptacog beta (rhFVIIa), new recombinant inhibitor agent treatment bleeding episodes (BEs).A Phase 3, randomized, cross-over...
The risk of childhood acute lymphoblastic leukaemia (ALL) was investigated in relation to breastfeeding patterns the Northern California Childhood Leukaemia Study. Data collected by self-administered and in-person questionnaires from biological mothers cases (age 0–14 years) period 1995–2002 were matched birth certificate controls on date birth, sex, Hispanic ethnic status, maternal race. Ever compared never not associated with ALL at ages 1–14 years (odds ratio=0.99; 95% CI=0.64–1.55) 2–5...
Introduction Nuwiq ® (Human‐cl rh FVIII ) is a fourth generation recombinant , produced in human cell line, without chemical modification or protein fusion. No inhibitors developed studies with 201 previously treated patients haemophilia A ( HA ). The immunogenicity, efficacy and safety of untreated PUP s) severe are being assessed the ongoing NuProtect study. Methods study, conducted across 38 centres worldwide, evaluating 110 true s all ages ethnicities enrolled for study up to 100...
Ensuring hemostasis during invasive procedures is a challenge in patients with severe hemophilia A. This analysis evaluated efficacy and safety of BAY 94-9027, an extended-half-life recombinant factor VIII (FVIII), the surgical setting.Patients participating open-label 94-9027 clinical trial who underwent major surgery were included analysis. Investigator/surgeon assessment was primary outcome. In addition, information about FVIII use, levels perioperative period, bleeding complications...
Hemophilia B is a genetic disease caused by mutation of the gene for coagulation protein Factor IX. When severe, leads to spontaneous life-threatening bleeding episodes. Current therapy requires frequent intravenous infusions therapeutic recombinant or plasma-derived concentrates containing Alprolix™ (recombinant IX Fc fusion protein), preparation that has been engineered prolonged half-life in circulation, completed pivotal clinical trials and approved recently USA, Canada, Australia Japan...